|
|||||
|
|
The Evolution of HCV Treatment in Taiwan |
|
| Authors: | Chung-Feng Huang Wan-Long Chuang Ming-Lung Yu |
| Institution: | 1. Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 2. Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan 3. Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 4. Faculty of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan |
| Abstract: | The treatment strategies used in Taiwan for patients with chronic hepatitis C (CHC) have evolved from conventional interferon monotherapy, consensus interferon therapy, conventional interferon/ribavirinand to pegylated interferon/ribavirin combination therapy. In the past two decades, the sustained virological response (SVR) rate in Taiwanese patients improved from 6 to 75-90 %. By following genotype-guided therapy, an SVR rate of 75-80 % and 85-95 % could be achieved in Taiwanese patients with HCV-1 and HCV-2 infections, respectively. The study of HCV viral kinetics has facilitated studies in Taiwan regarding response-guided therapy with tailored regimens. The majority of Taiwanese patients can be treated successfully with pegylated interferon/ribavirin. The application of IL-28B genetic tests and the insight provided by the viral kinetics might aid in selecting the best candidates for treatment with direct antivirals in the near future in Taiwan. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |